BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Taiho Oncology readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Taiho Oncology's drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04093570-2362@assetmemo.bio
DTSTAMP:20261121T005941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT04093570
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2\, Acute Myeloid Leuk
 emia.\nStudy: A Study for Participants Who Participated in Prior Clinical 
 Studies of ASTX727 (Standard Dose)\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/decitabine-
 cedazuridine-inqovi#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04093570
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
